(407) Preclinical Evaluation of Human Somatostatin Receptor 4 (hSSTR4) Agonist CNTX-0290 for Mixed Pain Conditions

CNTX-0290 is an oral, nonopioid hSSTR4 agonist under investigation for analgesia. Activity was assessed in acute, nociceptive, and neuropathic rat pain models. In the Complete Freund's Adjuvant (CFA) model, maximum efficacy of CNTX-0290 0.03 –3 mg/kg vs vehicle was compared with indomethacin 30 mg/kg and celecoxib 10 mg/kg; minimal effective dose (MED) was determined. In the monosodium iodoacetate (MIA) osteoarthritis model, weight-bearing deficit (WBD) was assessed following CNTX-0290 0.01–30 mg/kg administration.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research